Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age18-65
SponsorUniversiti Putra Malaysia
About this trial
Patients with psychiatric disorders, including depression, anxiety, and schizophrenia, often require antipsychotic medications for symptom management. However, metabolic changes, especially weight gain, are a common and challenging side effect of many antipsychotics. Aripiprazole, an atypical antipsychotic, has shown promise in mitigating this adverse effect when used in combination with other antipsychotic medications.
Eligibility criteria
Qualifiers
Females aged 18-65 years diagnosed with a mental health condition necessitating antipsychotic treatment.
Diagnosis of Schizophrenia or Schizoaffective Disorder
On stable doses of atypical antipsychotics, either Olanzapine, Clozapine, or Risperidone for at least 1 month
Willingness to comply with the study protocol.
Disqualifiers
Pregnancy or lactation.
Severe medical conditions impacting weight or metabolism.
Previous intolerance or contraindications to Aripiprazole.
Non-compliant with prescribed medications
Trial design
Treatments tested in this trial
- Adjunctive Aripiprazole for improving Weight and Metabolic Outcomes in Females
Treatment groups
600 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov